Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Here’s the results from the abstract presented this week at ASH

Twenty-two patients were evaluable for response, 1 patient is currently on therapy. The ORR in the total, non-PTCL and PTCL populations was 59%; 33% (no CR) and 77% respectively. Of the PTCL patients 4/13 (31%) achieved a CR, 6/13 (46%) achieved a PR, and 1 patient had stable disease. The mean duration of response (DOR) for all patients on the study (N=13) was 6.1 months (1.1 – 26.5), for the non-PTCL population (N=3) was 4.8 m (1.1-11) and for the PTCL population (N=10) was 6.55 months (range 1.6 – 26.5 +ongoing). The mean progression free survival (PFS) for all patients on study (N=26) was 4.8 m (.3 – 30.2), for the non-PTCL population (N=13) was 2.8 m (0.3-14.5), and for the PTCL population was 6.13 months (range 1.5 – 30.2 +ongoing).

Results were similar to the results presented 6 months earlier at ASCO. Note that this combo doesn’t work that well in B cell lymphomas. Seems like a completely different MoA in PTCLs as the vimeo.com/110122034 video noted and that’s why they will continue the Ph 2 part of the study in PTCL only.